Category Archives: General Interest

Decentralized R&D the “winning strategy”? – Apple begs to differ

There is a provocative piece in Aug 20 2012 issue (by Connie Guglielmo) of Forbes on Apple’s R&D, countering Pharma (and Tech) trend of decentralizing such efforts. Besides creating many high-level jobs and even more $B, is this creating a … Continue reading

Posted in General Interest, New R&D models | Leave a comment



Another R&D model sea-change?

Reflections on GSK’s new R&D model collaborating with top “academic superstars” Continue reading

Posted in General Interest, New R&D models | 1 Comment



Continued laments on R&D performance

Poor performance of Pharma R&D seems to have never left the newsservices or the hearts of all in the industry.  It is interesting to see the stories of 2011 echoing back for a decade.  Here are some current “news” items … Continue reading

Posted in Core Learnings, Financial, General Interest, Uncategorized | 1 Comment



McKinsey article hits close to home…

While I have been using the name “R&D Returns” for years, I welcome this article from McKinsey.  Here, they call attention to the value of balanced R&D architecture and management.  Some of the sea-change tools cited on my home page here … Continue reading

Posted in Financial, General Interest, Research | Tagged , , | Leave a comment



The R&D Returns “Ceiling”

BioPharma firms vary greatly in their ability to bring novel therapies to market – what causes some to underperform? Continue reading

Posted in General Interest, In the Pipeline | Tagged , , , | 3 Comments